These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1271 related articles for article (PubMed ID: 30290956)
1. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956 [TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473 [TBL] [Abstract][Full Text] [Related]
3. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Gil-Jimenez A; van Dorp J; Contreras-Sanz A; van der Vos K; Vis DJ; Braaf L; Broeks A; Kerkhoven R; van Kessel KEM; Ribal MJ; Alcaraz A; Wessels LFA; Seiler R; Wright JL; Mengual L; Boormans J; van Rhijn BWG; Black PC; van der Heijden MS Eur Urol; 2023 Apr; 83(4):313-317. PubMed ID: 35965206 [TBL] [Abstract][Full Text] [Related]
4. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy. Grivas P; Koshkin VS; Chu X; Cole S; Jain RK; Dreicer R; Cetnar JP; Sundi D; Gartrell BA; Galsky MD; Woo B; Li-Ning-Tapia E; Hahn NM; Carducci MA Eur Urol Oncol; 2024 Aug; 7(4):914-922. PubMed ID: 38155060 [TBL] [Abstract][Full Text] [Related]
5. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431 [TBL] [Abstract][Full Text] [Related]
6. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739 [TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762 [TBL] [Abstract][Full Text] [Related]
8. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841 [TBL] [Abstract][Full Text] [Related]
10. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y; Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010 [TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. Baras AS; Gandhi N; Munari E; Faraj S; Shultz L; Marchionni L; Schoenberg M; Hahn N; Hoque MO; Berman D; Bivalacqua TJ; Netto G PLoS One; 2015; 10(7):e0131245. PubMed ID: 26230923 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute. Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111 [TBL] [Abstract][Full Text] [Related]
14. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Plimack ER; Tangen C; Plets M; Kokate R; Xiu J; Nabhan C; Ross EA; Grundy E; Choi W; Dinney CPN; Lee IC; Fong M; Scott Lucia M; Daneshmand S; Theodorescu D; Goldkorn A; Lerner SP; Flaig TW; McConkey DJ Eur Urol; 2024 Oct; 86(4):297-300. PubMed ID: 39003201 [TBL] [Abstract][Full Text] [Related]
15. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205 [TBL] [Abstract][Full Text] [Related]
16. Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. Lotan Y; de Jong JJ; Liu VYT; Bismar TA; Boorjian SA; Huang HC; Davicioni E; Mian OY; Wright JL; Necchi A; Dall'Era MA; Kaimakliotis HZ; Black PC; Gibb EA; Boormans JL J Urol; 2022 Mar; 207(3):541-550. PubMed ID: 34643090 [TBL] [Abstract][Full Text] [Related]
17. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we? Osanto S; Álvarez Gómez de Segura C Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716 [TBL] [Abstract][Full Text] [Related]
19. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan. Mitsui Y; Okawa M; Hori S; Uetani M; Kasahara M; Yamabe F; Kobayashi H; Nagao K; Nakajima K Int J Urol; 2024 Sep; 31(9):1030-1037. PubMed ID: 38819073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]